Table 1.
Anti-fracture efficacy of strontium ranelate
Fracture | Duration (yrs) | RR (95% CI) |
---|---|---|
Vertebral | 1 | 0.51 (0.36, 0.74) |
Vertebral | 3 | 0.59 (0.48, 0.73) |
Vertebral | 4 | 0.67 (0.53, 0.81) |
Clinical vertebral | 1 | 0.48 (0.29, 0.80) |
Clinical vertebral | 3 | 0.62 (0.47, 0.83) |
Non-vertebral | 3 | 0.84 (0.70, 0.99) |
Non-vertebral | 5 | 0.85 (0.73, 0.99) |
Hip (post hoc)a | 3 | 0.64 (0.41, 0.99) |
Hip (post hoc)b | 5 | 0.57 (0.33, 0.97) |
aAge >74 yrs; t-score hip ≤ − 2.4 (NHANES). bAge >74 yrs; t-score hip and spine ≤ − 2.4 (NHANES).